Overview

The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.

Status:
Recruiting

Trial end date:
2025-06-30

Target enrollment:

Participant gender:

Summary

This is a prospective, single-center, open-label clinical study designed to evaluate the efficacy and safety of the Zanubrutinib, Lenalidomide and Rituximab (ZR2) versus rituximab combined with CHOP or CDOP (R-CHOP or R-CDOP) in elderly patients with diffuse large B cell lymphoma treated for the first time.

Phase:

Phase 2

Details

Lead Sponsor:

First Affiliated Hospital of Wenzhou Medical University

Treatments:

Lenalidomide
Rituximab
Zanubrutinib